Skip to main content

Tezepelumab Effective for Severe, Uncontrolled Asthma

FRIDAY, May 20, 2022 -- Tezepelumab treatment is associated with higher levels of on-treatment clinical responses than placebo among individuals with severe, uncontrolled asthma, according to a study presented at the American Thoracic Society 2022 International Conference, held from May 13 to 18 in San Francisco.

Njira Lugogo, M.D., from the University of Michigan in Ann Arbor, and colleagues conducted a prespecified exploratory analysis to assess the proportion of patients with on-treatment clinical responses in the NAVIGATOR trial. The analysis included patients (12 to 80 years old) who had been randomly assigned (1:1) to receive tezepelumab (471 participants) or placebo (449 participants) subcutaneously every four weeks for 52 weeks.

The researchers found that across the response criteria, the proportion of responders was higher in the tezepelumab group versus the placebo group for exacerbations (85.4 versus 67.5 percent; odds ratio, 2.82), Asthma Control Questionnaire-6 total score (86.9 versus 76.6 percent; odds ratio, 2.05), prebronchodilator forced expiratory volume in one second (60.3 versus 49.9 percent; odds ratio, 1.52), and Clinical Global Impression of Change score (81.5 versus 67.7 percent; odds ratio, 2.21). The tezepelumab group had a higher proportion of on-treatment complete responders versus the placebo group (48.2 versus 25.3 percent; odds ratio, 2.78).

"Patients are always interested in understanding the potential outcomes following therapy initiation and our results can guide clinicians in informing patients about the likelihood of both individual and complete response to therapy," Lugogo said in a statement.

The study was funded by AstraZeneca and AMGEN, the manufacturers of tezepelumab.


More Information

© 2022 HealthDay. All rights reserved.

Read this next

Regulatory, Patent Reform Needed for Inhalers for Asthma, COPD

FRIDAY, May 20, 2022 -- Of the 62 inhalers approved by the U.S. Food and Drug Administration since 1986, few have offered novel drug innovations, according to a study published...

Albuterol Plus Budesonide Cuts Exacerbations in Asthma

TUESDAY, May 17, 2022 -- For patients with moderate-to-severe asthma, as-needed use of a fixed combination of albuterol and budesonide is associated with a lower risk for severe...

Lack of Asthma Control More Likely With COVID-19-Related Anxiety

WEDNESDAY, May 11, 2022 -- Uncontrolled asthma is more likely among adults with asthma who have higher anxiety due to COVID-19, while most parents of children with food allergy...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.